Published in Cancer Res on July 01, 2007
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
Homeostasis and inflammation in the intestine. Cell (2010) 4.60
Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol (2010) 4.07
The interleukin-1 family: back to the future. Immunity (2013) 3.90
Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol (2010) 2.58
Securing the immune tightrope: mononuclear phagocytes in the intestinal lamina propria. Nat Rev Immunol (2010) 2.02
Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron (2010) 1.96
A systems view of epithelial-mesenchymal transition signaling states. Clin Exp Metastasis (2010) 1.95
Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis (2010) 1.79
NF-κB in the regulation of epithelial homeostasis and inflammation. Cell Res (2010) 1.72
Role of Toll-like receptors in gastrointestinal malignancies. Oncogene (2008) 1.69
Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis (2009) 1.53
An innately dangerous balancing act: intestinal homeostasis, inflammation, and colitis-associated cancer. J Exp Med (2010) 1.42
Animal models of colitis-associated carcinogenesis. J Biomed Biotechnol (2011) 1.33
The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response. J Immunol (2009) 1.19
The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J Transl Med (2010) 1.14
Opposing Functions of Classic and Novel IL-1 Family Members in Gut Health and Disease. Front Immunol (2013) 1.11
Loss of single immunoglobulin interlukin-1 receptor-related molecule leads to enhanced colonic polyposis in Apc(min) mice. Gastroenterology (2010) 1.04
SIGIRR, a negative regulator of TLR/IL-1R signalling promotes Microbiota dependent resistance to colonization by enteric bacterial pathogens. PLoS Pathog (2013) 1.02
Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8. Proc Natl Acad Sci U S A (2015) 1.00
TIR8/SIGIRR is an Interleukin-1 Receptor/Toll Like Receptor Family Member with Regulatory Functions in Inflammation and Immunity. Front Immunol (2012) 0.99
Inciting inflammation: the RAGE about tumor promotion. J Exp Med (2008) 0.99
Decoys and Regulatory "Receptors" of the IL-1/Toll-Like Receptor Superfamily. Front Immunol (2013) 0.96
Suppression of innate inflammation and immunity by interleukin-37. Eur J Immunol (2016) 0.94
Cancer in inflammatory bowel disease: lessons from animal models. Curr Opin Gastroenterol (2012) 0.93
Differential regulation of Toll-like receptor signalling in spleen and Peyer's patch dendritic cells. Immunology (2010) 0.92
STAT2 contributes to promotion of colorectal and skin carcinogenesis. Cancer Prev Res (Phila) (2010) 0.92
Cytokines, IBD, and colitis-associated cancer. Inflamm Bowel Dis (2015) 0.91
Regulation of toll-like receptors in intestinal epithelial cells by stress and Toxoplasma gondii infection. Parasite Immunol (2008) 0.90
Down-regulation of single immunoglobulin interleukin-1R-related molecule (SIGIRR)/TIR8 expression in intestinal epithelial cells during inflammation. Clin Exp Immunol (2010) 0.90
Neutrophil infiltration favors colitis-associated tumorigenesis by activating the interleukin-1 (IL-1)/IL-6 axis. Mucosal Immunol (2014) 0.89
Role of Toll interleukin-1 receptor (IL-1R) 8, a negative regulator of IL-1R/Toll-like receptor signaling, in resistance to acute Pseudomonas aeruginosa lung infection. Infect Immun (2011) 0.89
Differential expression of key regulators of Toll-like receptors in ulcerative colitis and Crohn's disease: a role for Tollip and peroxisome proliferator-activated receptor gamma? Clin Exp Immunol (2015) 0.83
Polymorphisms in NFKB1 and TLR4 and interaction with dietary and life style factors in relation to colorectal cancer in a Danish prospective case-cohort study. PLoS One (2015) 0.81
Intersecting pathways in inflammation and cancer: Hepatocellular carcinoma as a paradigm. World J Clin Oncol (2012) 0.80
Human Colon Tumors Express a Dominant-Negative Form of SIGIRR That Promotes Inflammation and Colitis-Associated Colon Cancer in Mice. Gastroenterology (2015) 0.78
Blockade of MK2 is protective in inflammation-associated colorectal cancer development. Int J Cancer (2015) 0.78
SIGIRR, a negative regulator of colon tumorigenesis. Drug Discov Today Dis Mech (2012) 0.77
Regulatory Role of IL-1R8 in Immunity and Disease. Front Immunol (2016) 0.76
Therapeutic potential of SIGIRR in systemic lupus erythematosus. Rheumatol Int (2013) 0.76
Anti-inflammatory natural product goniothalamin reduces colitis-associated and sporadic colorectal tumorigenesis. Carcinogenesis (2016) 0.75
SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas. Hum Pathol (2015) 0.75
Lack of IL-1R8 in neurons causes hyperactivation of IL-1 receptor pathway and induces MECP2-dependent synaptic defects. Elife (2017) 0.75
Bifidobacterium adolescentis protects against necrotizing enterocolitis and upregulates TOLLIP and SIGIRR in premature neonatal rats. BMC Pediatr (2017) 0.75
Macrophage plasticity and polarization: in vivo veritas. J Clin Invest (2012) 13.44
Macrophage activation and polarization. Front Biosci (2008) 11.17
Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol (2006) 9.82
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol (2010) 9.59
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis (2009) 7.55
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer (2006) 5.60
Macrophage polarization in tumour progression. Semin Cancer Biol (2008) 4.62
The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol (2007) 3.95
Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med (2003) 3.91
Transcriptional profiling reveals complex regulation of the monocyte IL-1 beta system by IL-13. J Immunol (2005) 3.87
A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood (2005) 3.85
Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med (2003) 3.71
Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol (2005) 3.48
IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol (2003) 3.41
The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev (2008) 3.33
Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc Natl Acad Sci U S A (2009) 3.27
The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J Immunol (2004) 3.21
Cancer: Inflaming metastasis. Nature (2009) 3.09
Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med (2014) 3.08
Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci U S A (2009) 3.01
Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature (2002) 3.01
AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat Immunol (2011) 2.99
Cancer related inflammation: the macrophage connection. Cancer Lett (2008) 2.88
p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res (2006) 2.76
Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells. J Immunol (2005) 2.75
The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med (2007) 2.71
An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol (2010) 2.71
Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol (2003) 2.62
Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol (2010) 2.60
The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood (2003) 2.57
Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature (2007) 2.54
CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol (2009) 2.47
Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol (2011) 2.45
Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell (2013) 2.35
Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res (2004) 2.31
Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation (2004) 2.31
Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma. Cell (2013) 2.28
Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci Signal (2008) 2.27
Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program. J Immunol (2003) 2.24
The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica (2006) 2.19
Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation (2008) 2.18
Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. Blood (2013) 2.14
Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation (2009) 2.11
International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev (2013) 2.11
The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum (2008) 2.08
Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J Immunol (2010) 2.07
Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A (2004) 2.06
The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood (2007) 1.99
Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron (2010) 1.96
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 1.95
Pathways connecting inflammation and cancer. Curr Opin Genet Dev (2008) 1.95
Orchestration of metabolism by macrophages. Cell Metab (2012) 1.92
Tumor associated macrophages and neutrophils in cancer. Immunobiology (2013) 1.87
Chemokines and chemokine receptors: an overview. Front Biosci (Landmark Ed) (2009) 1.87
Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. Immunity (2005) 1.86
Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res (2002) 1.86
Cytokines as a key component of cancer-related inflammation. Cytokine (2008) 1.85
Cancer: inflammation by remote control. Nature (2005) 1.85
Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood (2011) 1.84
Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol (2002) 1.82
IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect (2004) 1.82
IL-1 family nomenclature. Nat Immunol (2010) 1.79
Cellular and molecular pathways linking inflammation and cancer. Immunobiology (2009) 1.78
Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol (2008) 1.76
Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med (2010) 1.75
Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol (2007) 1.75
Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol (2013) 1.74
Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol (2006) 1.72
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A (2005) 1.70
PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization. Development (2004) 1.68
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res (2010) 1.68
Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol (2003) 1.67